Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis

Published:2016-06 Issue: Volume:116 Page:149-158
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Lee Crystal Man Ying,Woodward Mark,Colagiuri Stephen

Funder

National Health and Medical Research Council Principal Research Fellowship

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference52 articles.

1. A new blood glucose management algorithm for type 2 diabetes. A position statement of the Australian Diabetes Society;Gunton;Med J Aust,2014

2. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis;Gross;Ann Intern Med,2011

3. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial;Hollander;Diabetes Obes Metab,2011

4. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations;Hutton;Ann Intern Med,2015

5. Assessing the quality of reports of randomized clinical trials: is blinding necessary?;Jadad;Control Clin Trials,1996

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association;Diabetes & Metabolism Journal;2024-07-31

2. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension;Diabetes & Metabolism Journal;2023-11-30

3. Integrating micellar HPLC and green analytical chemistry tools in greenness assessment of five commonly Co-formulated antidiabetic drugs;Sustainable Chemistry and Pharmacy;2023-10

4. Glucose‐lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types;Diabetes, Obesity and Metabolism;2023-08-07

5. Effective data-driven precision medicine by cluster-applied deep reinforcement learning;Knowledge-Based Systems;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3